Access
To read this story in full you will need to login or make a payment (see right).
Insight
Nature 436, 930-932 (18 August 2005) | doi:10.1038/nature04076; Published online 17 August 2005
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Senior Staff Scientist
- National Institute of Mental Health (NIMH)
- Bethesda, Maryland
Manager for the Recently Established Fly Facility
- Max-Planck-Institute of Immunobiology
- Freiburg Germany
introduction Unscrambling hepatitis C virus–host interactions
Francis V. Chisari1
Abstract
The human suffering exacted by the hepatitis C virus is enormous. Hundreds of thousands of people die each year from liver failure and cancer caused by this infection. There is no vaccine, and the available antiviral drugs are toxic, expensive and only partly effective. Progress has been hindered by the absence of cell culture and small-animal models of the infection. Nonetheless, recent advances have yielded several promising new antiviral drugs and enhanced the prospects of developing a vaccine. The recent development of a robust in vitro hepatitis C virus infection system will aid this search.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Hitching RIG to actionNature Immunology News and Views (01 Nov 2005)
Research HighlightsNature Biotechnology News and Views (01 Jul 2005)
See all 3 matches for News And Views